VHL vitasora health limited

serious buyer steps into virax market, page-3

  1. 1,219 Posts.
    lightbulb Created with Sketch. 599
    …yes, Maxter.

    And I notice that Transgene's MC stands at $A626.2m against a recently upgraded valuation by London-based Edison Investment Research of $A706.9m.

    Edison - which is close to Transgene - sees likelihood of success for TG4010 at 60%.

    Yet the firm has upgraded the probability of Novartis exercising its option to commercialize TG4010 from 60% to 80%.

    If Novartis decides to exercise the option it will need to pay Transgene $A1.1b.

    Transgene, in turn, will need to pay to Virax. And Virax will need to pay ANU/CSIRO.

    It seems to me that an investor wanting to plug into the success of the potential blockbuster lung cancer drug TG4010 has three main options:

    1. Buy Novartis, MC $A305.8b;

    2. Buy Transgene, MC $A626.2m;

    3. Buy Virax, MC $8.3m.

    I'm glad I've chosen option #3.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.6¢
Change
0.000(0.00%)
Mkt cap ! $44.68M
Open High Low Value Volume
2.4¢ 2.6¢ 2.4¢ $36.15K 1.445M

Buyers (Bids)

No. Vol. Price($)
9 425044 2.4¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 146386 2
View Market Depth
Last trade - 16.10pm 07/08/2025 (20 minute delay) ?
VHL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.